Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jun 8;115(6):605-607.
doi: 10.1093/jnci/djac016.

Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?

Michael T Milano  1 , Joseph K Salama  2 , Steven J Chmura  3
Affiliations
Comment

Should We Target Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer With Radiotherapy Before Administering Targeted Systemic Therapy?

Michael T Milano et al. J Natl Cancer Inst. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Wang X-S, Bai Y-F, Verma V, et al.Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC. J Natl Cancer Inst. 2023;115(6):742–748. - PMC - PubMed
    1. Gomez DR, Blumenschein GR Jr, Lee JJ, et al.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682. - PMC - PubMed
    1. Gomez DR, Tang C, Zhang J, et al.Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019;37(18):1558–1565. - PMC - PubMed
    1. Iyengar P, Wardak Z, Gerber DE, et al.Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. - PMC - PubMed
    1. Phillips R, Shi WY, Deek M, et al.Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659. - PMC - PubMed

MeSH terms